A股異動 | 世名科技(300522.SZ)跌逾7% 紅塔創新擬減持不超358萬股
格隆匯1月25日丨世名科技(300522.SZ)現報22.7元,跌7.01%,暫成交2810萬元,最新總市值41億元。世名科技上週五(22日)晚間公佈,公司股東紅塔創新計劃自減持計劃公吿之日起3個交易日後的6個月內,通過集中競價交易或大宗交易方式減持不超過公司股份358萬股,即不超過剔除世名科技回購專用賬户股份數量後總股本比例的2%。值得一提的是,紅塔創新自2020年9月2日-2021年1月19日期間通過集中競價方式已減持公司股份36.9838萬股,佔公司總股本的0.206%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.